TROP2 PET to choose and sequence TROP2 ADCs
Use a whole-body TROP2 scan instead of a single tissue stain to decide which patients get a TROP2 ADC, which one, and when to switch.
IHC on archival tissue failed to predict sacituzumab benefit. A PET tracer would capture heterogeneity across lesions, current (not archival) expression, and antigen loss at progression.
For hormone-receptor-positive metastatic breast cancer that has already had chemotherapy, Dato-DXd controls the disease for longer with fewer severe side effects than chemotherapy, but does not help patients live longer, so it is not a standard option here. The result is a reminder that progression-free survival is a surrogate; regulators and clinicians should wait for survival data before adopting an ADC in a setting where later therapies are effective.
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
Pages like this
not linked directly; found by shared links- TrialASCENT
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, TROP2.
- TrialTROPION-Breast02
Shares TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan, Triple-negative breast cancer (TNBC).
- TrialASCENT-03
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).
- PersonSara M. Tolaney
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, Datopotamab deruxtecan, TROP2.
- PersonHope S. Rugo
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, TROP2, Antibody-drug conjugate (ADC).
- TrialASCENT-04 / KEYNOTE-D19
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast01
Shares TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan.
- PairingCaution: TOP1 ADC immediately after TOP1 ADC
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, Datopotamab deruxtecan, Triple-negative breast cancer (TNBC).